Summary:
|
|
Now On Demand.
Learn what drove biotech performance in the pivotal year of 2021, and why having the proper benchmark for this unique industry is more important than ever. Along with a special guest from Nasdaq-listed BioMarin Pharmaceutical, take a deep dive into some of the cutting-edge innovation happening within the space, especially as it relates to gene therapy for the treatment of rare diseases. More broadly, place the incredible achievements to tame Covid-19 into the proper context of biotech’s next stage of evolution, as an array of technological advancements begin to accelerate our understanding and treatment of illness.
|
|
Speakers:
|
 |
Mark Marex, CFA
Senior Specialist, Index Research & Development
Nasdaq Investment Intelligence
|
|
Mark Marex works as a Senior Specialist in Index Research & Development, splitting his efforts between producing original content in support of existing index products, as well as developing new indexes for launch and commercialization. Before joining Nasdaq Global Indexes in 2019, Mark was an emerging fund manager of a systematic long/short US large-cap equity strategy, and co-founded Roundtree Capital Management in 2016. Prior to that, Mark spent eight years at Citigroup in New York, working as a Product Manager of FX in the Investor Services business; as a Vice President of Client Strategy & Analytics in the Investment Banking division; and when he first started in 2008, as a Product Controller in Structured Credit.
Mark graduated with a Bachelor of Science in Economics from Duke University in 2008, and has been a CFA charter holder since 2012. He is passionate about innovation in the world of indexing, ETFs, and quantitative investing. He resides in New Jersey with his wife. |
 |
Rene Reyna, CFP®
Head of Thematic & Specialty Product Strategy ETFs and Indexed Strategies
Invesco
|
|
Rene Reyna is Head of Thematic and Specialty Product Strategy for the Exchange-Traded Funds (ETFs) and Indexed Strategies teams at Invesco. Mr. Reyna joined Invesco in 2010. Prior to his current role, he was head of Product Strategy and Development for Invesco’s Unit Trust business. He served as a Unit Trust product specialist prior to that role. Before joining the firm, Mr. Reyna was an investment representative with JPMorgan Chase. He has been in the financial services industry since 2005. Mr. Reyna earned a BS degree in financial planning and counseling from Purdue University. He is a Certified Financial Planner® (CFP) and holds the Series 6, 7, 24, 63, and 66 registrations. |
 |
Brian Mueller
Executive Vice President, Chief Financial Officer
BioMarin
|
|
Brian R. Mueller joined BioMarin in December 2002 and currently serves as Executive Vice President, Chief Financial Officer. In his role, he is responsible for managing all Finance and Information Management teams. Prior to this, he served as Senior Vice President, Finance and Chief Accounting Officer and as Group Vice President, Corporate Controller.
Before joining BioMarin, Mr. Mueller worked for KPMG as a senior manager in the firm’s audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.
From June 2014 to May 2020, Mr. Mueller was a member of the board of directors of Anthera Pharmaceuticals, Inc., a previously public biopharmaceutical company, where he also served as Chairman of the Audit Committee. Mr. Mueller received a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants. |
